Seeking Alpha

PerkinElmer (PKI) says it's completed the acquisition of Shanghai Haoyuan Biotech, a China-based...

PerkinElmer (PKI) says it's completed the acquisition of Shanghai Haoyuan Biotech, a China-based infectious disease diagnostics company, for $38M in cash plus future consideration based on the achievement of revenue-based targets. PKI says the deal should be immaterial to adjusted earnings for the remainder of 2012 and 2013 and accretive beginning in 2014.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector